after the stock received an upgrade from Mizuho to "buy" from "neutral" and a price-target hike to $27 from $15, with the analyst in coverage calling the company's portfolio "Mylan-like." In response, VRX is up 2.8% at $21.40, at last check. …
"Supply constraints" prevented adequate stock, according to the society's notice ... In response to the letter, Mylan said that the FDA warning did not "affect Pfizer's ability to manufacture and supply" products from the facility.
KVIA11d
Pharmacies nearly out of stock of regular dosage EpiPens with no idea how soon ... citing “manufacturing delays,” with date of availability to be determined. Mylan, the maker of EpiPens, issued a statement acknowledging what it calls …
Mylan NV(MYL) rose 3.8%. It reported first-quarter earnings ... pacific-stocks-hold-the-line-after-trump-pulls-out-of-iran-deal-2018-05-08), while European stock (http://www.marketwatch.com/story/european-equities-rally-boosted-by-gains-for-oil …
Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views. (Sharecast News) - American speciality pharmaceuticals company Mylan reported a fall in revenue for first-quarter on Wednesday but upped its full year …
Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $35.40 to a high of $37.05. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $36.47 on volume of 3.0 million shares. …
That was good for a $0.13 credit. Calls tend to profit when a stock moves higher because they fix the price where investors can buy shares. That seems to have …